Olaparib (Tablet) and Bevacizumab Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Olaparib (Tablet) and Bevacizumab Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. 14

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
Sensitivity (+) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
Sensitivity (+) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
Sensitivity (+) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
Sensitivity (+) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
Sensitivity (+) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
Sensitivity (+) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
Sensitivity (+) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
Sensitivity (+) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
Sensitivity (+) HRD High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
Sensitivity (+) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib